Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on May 20, 2023 10:55am
166 Views
Post# 35457704

RE:RE:RE:RE:RE:RE:RE:New Press Release - Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.

RE:RE:RE:RE:RE:RE:RE:New Press Release - Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.

In fact they dont own 10.1%.That would happen only if and when they exercise the warrants which are way  out of the money at this time.
Appears to be non consequential based on what we know but we dont know everything!!!

 


SPCEO1 wrote: It is a Canadian filing and it is from November 2022. One possible explanation is they didn't realize they had to file this and are just getting around to it. So it is more a late filing than an early one, if that guess is right.

But what is going on that Soleus just realized they should have made this filing earlier? Did their lawyer just accidentally stumble over this requirement or are they involved in something that caused their lawyer to be making sure all their filings are in correct order before they do something else? If that is the case we should know soon enough what is going on.
qwerty22 wrote: They own 10.01%. Seems like a deliberate attempt to go over the 10% mark with a 7000 share purchase. Is there a reason to do that? Provoke a reaction?



 

<< Previous
Bullboard Posts
Next >>